Navigation Links
Cynosure, Inc. Prices Public Offering of Class A Common Stock

WESTFORD, Mass., Nov. 16, 2012 /PRNewswire/ -- Cynosure, Inc. (NASDAQ: CYNO) (the "Company"), a leader in laser- and light-based treatments for minimally invasive and non-invasive aesthetic applications, today announced the pricing of an underwritten registered public offering of 2,600,000 shares of its class A common stock at a public offering price of $20.50 per share. In addition, El.En. S.p.A. is selling 600,000 shares of the Company's class A common stock at a public offering price of $20.50 per share.  The offering is expected to close on or about November 21, 2012, subject to customary closing conditions.

Leerink Swann LLC, the underwriter for this offering, has the option for a period of up to 30 days from the date of the prospectus supplement to purchase up to an additional 240,000 shares from the Company and up to an additional 240,000 shares from El.En. S.p.A. at the public offering price less underwriting discounts and commissions.

The Company intends to use the net proceeds from the shares sold in this offering for general corporate purposes and to fund its potential acquisition of complementary products, technologies or businesses.  The Company will not receive any proceeds from the sale of the shares by El.En. S.p.A.

The shares will be issued pursuant to a shelf registration statement previously filed with the Securities and Exchange Commission (the "SEC") and declared effective on October 26, 2012.  A preliminary prospectus supplement and accompanying base prospectus related to the offering have been filed with the SEC.  A final prospectus supplement related to the offering will be filed with the SEC. Copies of the final prospectus supplement, when available, and accompanying base prospectus may be obtained from Leerink Swann LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by calling (800) 808-7525, ext. 4814.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company, nor shall there be any offer or sale of securities in any state or jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any state or jurisdiction. 

About Cynosure, Inc.
Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and pigmented lesions, remove multi-colored tattoos, rejuvenate the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite and treat onychomycosis. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulse dye, Q-switched, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991. For corporate or product information, contact Cynosure at 800-886-2966.

Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the closing of the Company's public offering and the intended use of proceeds, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including levels of demand for procedures performed with Cynosure products and for Cynosure products themselves, Cynosure's ability to maintain its profitability, competition in the aesthetic laser industry, general business and economic conditions, effects of acquisitions that Cynosure has made or may make, Cynosure's ability to develop and commercialize new products, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, and economic, market, technological and other factors discussed in Cynosure's most recent Quarterly Report on Form 10-Q, which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, although Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

Scott Solomon

Vice President

Sharon Merrill


SOURCE Cynosure, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cynosure, Inc. Announces Proposed Public Offering of Class A Common Stock
2. Isis Pharmaceuticals Prices Offering of $201.25 Million of 2 3/4% Convertible Senior Notes, Including Exercise in Full of Over-Allotment Option
3. Solta Medical, Inc. Prices $15 Million Public Offering of Common Stock
4. MAP Pharmaceuticals, Inc. Prices Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Novelos Therapeutics Prices $5.4 Million Public Offering
7. Albemarle to increase ibuprofen prices
8. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
9. TNI BioTech, Inc. Signs Exclusive Distributor Agreement for Federal Republic of Nigeria with G-Ex Technologies/St. Maris Pharma & GB Pharma Holdings LLC
10. AspenBio Pharma Announces Pricing of Public Offering of 1,476,000 Shares of Common Stock
11. AspenBio Pharma Announces Proposed Public Offering
Post Your Comments:
(Date:10/12/2015)... MENLO PARK, Calif. , Oct. 12, ... of R&D and Chief Scientific Officer of ... leading biotechnology company in the emerging field ... BioPharma Dealmakers webcast, sponsored in part by ... medicine. Dr. Lebkowski will discuss the progress ...
(Date:10/12/2015)... 12, 2015 The global infertility treatment ... million by 2020 from USD 1,822.32 million in ... and 2020. By product, the market includes antivibration ... systems, micromanipulator systems, ovum aspiration pumps, sperm analyzer ... market is segmented into in vitro fertilization, artificial ...
(Date:10/12/2015)... -- Elbit Imaging Ltd. ("EI" or the "Company") ... of directors approved a program to repurchase up to NIS ... Notes and Series I Notes, which are traded on the ... Company will have a significant preference to the purchase Series ... time in the open market on the Tel Aviv Stock ...
Breaking Medicine Technology:
(Date:10/13/2015)... , ... October 13, 2015 , ... ... review of Anik Singal's newly launched "Publish Academy" training course . Singal's ... business opened for enrollment today, and marketers around the Internet are weighing in ...
(Date:10/13/2015)... ... October 13, 2015 , ... T-System and Centegra ... than 59,000 emergency department visits per year, today announced the successful and rapid ... improve clinical, operational and financial outcomes. , In less than four ...
(Date:10/13/2015)... ... , ... Local Gold’s Gym franchise owner, Bryce Berry, received the Visionary of ... owns and operates Gold's Gym Cheyenne in Cheyenne, Wyoming, received the award ... States. A brand leader in global fitness, Gold’s Gyms are located worldwide. Every fitness ...
(Date:10/13/2015)... , ... October 13, 2015 , ... ... Affinity have developed valuable new strategies for enrolling and serving insurance consumers who ... to obtain health insurance and pay monthly premiums. In “Health Plan Engagement Strategies: ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... team: Debbie Vereb has been named the organization’s Executive Vice President of ... have been hired to key leadership roles in the company. , Debbie Vereb’s ...
Breaking Medicine News(10 mins):